BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

Suppose a cancer patient has been told that he would be free of cancer cells and return to his normal life; that would be the ...

Researchers advance CAR T cell therapy for solid tumors by innovating ways to overcome the unique barriers of solid tumor ...

Most cancer treatments—from chemotherapies to engineered immune cells—have a host of side effects, in large part because they ...

Nektar continues to make progress with rezpegaldesleukin, with results from phase 2 atopic dermatitis study expected in H1'25 ...

Autolus Therapeutics has secured US Food and Drug Administration (FDA) approval for Aucatzyl (obecaktagene autoleucel), its ...

Glioblastoma is the most common kind of malignant brain tumor in adults. So far, no treatment has been able to make this ...

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on CARGO Therapeutics, Inc. (CRGX – Research Report) today and set a ...

Researchers have developed an innovative CAR T-cell therapy to combat glioblastoma, the most common malignant brain tumor in ...

Researchers at the University of Basel have developed CAR T-cells that target glioblastoma, a notoriously aggressive brain ...

T-cell therapy is a revolutionary immunotherapy approach in which T cells are genetically modified to express a receptor that ...

Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this ...